Gossamer Bio, Inc.(GOSS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,931 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GOSS Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for Gossamer Bio, Inc. (GOSS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GOSS at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,931 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.9) and balance sheet strength (1.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Gossamer Bio, Inc. reports quarterly revenue of $9.2M, net income of $16.9M, free cash flow of $-39.4M. Top institutional holders of GOSS by reported 13-F value include TANG CAPITAL MANAGEMENT, D. E. Shaw, 683 Capital Management, based on the most recent SEC filings. GOSS trades on the Nasdaq exchange and files with the SEC under CIK 1728117. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GOSS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gossamer Bio, Inc. directly from SEC EDGAR. Gossamer Bio, Inc.'s 13F Pro composite quality score has ranged between 6 and 27 since 2025, currently 8.2 — a declining long-term trajectory across 53 quarterly and live scoring snapshots.
Revenue
Q2 2026
$9.2M
Net Income
Q2 2026
$16.9M
Free Cash Flow
Q2 2026
$-39.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-57.7% YoYNet Income
-201.4% YoYOperating Income
-184.9% YoYEPS (Diluted)
-200.0% YoYTotal Assets
-45.4% YoYTotal Debt
Op. Cash Flow
-4838.5% YoYFree Cash Flow
-4840.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $48.5M -57.7% | $114.7M | $0.00 | $0.00 | — | — |
| Net Income | $-170.4M -201.4% | $-56.5M +68.6% | $-179.8M +21.6% | $-229.4M +2.0% | $-234.0M +3.8% | $-243.4M |
| Operating Income | $-170.7M -184.9% | $-59.9M +67.4% | $-183.8M +15.9% | $-218.6M -1.1% | $-216.1M +7.6% | $-234.0M |
| EPS (Diluted) | $-0.75 -200.0% | $-0.25 +78.8% | $-1.18 +56.5% | $-2.71 +13.4% | $-3.13 +11.8% | $-3.55 |
| Total Assets | $172.2M -45.4% | $315.3M +1.1% | $311.9M +14.5% | $272.4M -20.7% | $343.7M -36.3% | $539.4M |
| Total Debt | — | $0.00 -100.0% | $12.4M -47.3% | $23.6M -18.8% | $29.1M +1.2% | $28.7M |
| Operating Cash Flow | $-171.3M -4838.5% | $-3.5M +97.8% | $-159.2M +14.9% | $-187.0M +1.0% | $-188.9M -7.1% | $-176.4M |
| Free Cash Flow | $-171.3M -4840.7% | $-3.5M +97.8% | $-159.2M +15.1% | $-187.4M +1.6% | $-190.4M -7.1% | $-177.9M |
Get alerted when GOSS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Gossamer Bio, Inc. including:
Top Institutional Holders of GOSS
TANG CAPITAL MANAGEMENT LLC
$11.5M17,841,000 shD. E. Shaw & Co., Inc.
$6.7M40,959,285 sh683 Capital Management, LLC
$6.5M39,198,868 shDeepCurrents Investment Group LLC
$6.0M37,665,073 shContext Capital Management, LLC
$4.8M28,946,459 shWorth Venture Partners, LLC
$4.1M25,017,881 shAQR CAPITAL MANAGEMENT LLC
$2.6M15,629,993 shGSA CAPITAL PARTNERS LLP
$2.5M14,986,947 shWOLVERINE ASSET MANAGEMENT LLC
$2.1M12,894,746 shRENAISSANCE TECHNOLOGIES LLC
$1.9M11,629,896 sh
| Fund | Value | Shares |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $11.5M | 17,841,000 |
| D. E. Shaw & Co., Inc. | $6.7M | 40,959,285 |
| 683 Capital Management, LLC | $6.5M | 39,198,868 |
| DeepCurrents Investment Group LLC | $6.0M | 37,665,073 |
| Context Capital Management, LLC | $4.8M | 28,946,459 |
| Worth Venture Partners, LLC | $4.1M | 25,017,881 |
| AQR CAPITAL MANAGEMENT LLC | $2.6M | 15,629,993 |
| GSA CAPITAL PARTNERS LLP | $2.5M | 14,986,947 |
| WOLVERINE ASSET MANAGEMENT LLC | $2.1M | 12,894,746 |
| RENAISSANCE TECHNOLOGIES LLC | $1.9M | 11,629,896 |
Companies Similar to GOSS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Karyopharm Therapeutics Inc.
PRECISION BIOSCIENCES INC
Lyell Immunopharma, Inc.
FATE THERAPEUTICS INC
Taysha Gene Therapies, Inc.
CRESCENT BIOPHARMA, INC.
Pulmonx Corp
Stoke Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put GOSS on your watchlist
Track score changes the day Gossamer Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GOSS a good stock to buy?
13F Pro's AI-powered analysis of Gossamer Bio, Inc. (GOSS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GOSS are available on the GOSS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GOSS is classified as a mid company.
Which hedge funds own GOSS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GOSS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Gossamer Bio, Inc.'s investment landscape.